Karasawa Tadayoshi, Takahashi Masafumi
Division of Inflammation Research, Center for Molecular Medicine, Jichi Medical University.
J Atheroscler Thromb. 2017 May 1;24(5):443-451. doi: 10.5551/jat.RV17001. Epub 2017 Mar 4.
Inflammation with macrophage infiltration is a key feature of atherosclerosis. Although the mechanisms had been unclear, emerging evidence unveiled that NLRP3 inflammasomes, which regulate caspase-1 activation and subsequent processing of pro-IL-1β, trigger vascular wall inflammatory responses and lead to progression of atherosclerosis. NLRP3 inflammasomes are activated by various danger signals, such as cholesterol crystals, calcium phosphate crystals, and oxidized low-density lipoprotein in macrophages, to initiate inflammatory responses in the atherosclerotic lesion. Recent studies have further clarified the regulatory mechanisms and the potential therapeutic agents that target NLRP3 inflammasomes. In this study, we reviewed the present state of knowledge on the role of NLRP3 inflammasomes in the pathogenesis of atherosclerosis and discussed the therapeutic approaches that target NLRP3 inflammasomes.
伴有巨噬细胞浸润的炎症是动脉粥样硬化的关键特征。尽管其机制尚不清楚,但新出现的证据表明,调节半胱天冬酶-1激活及随后前白细胞介素-1β加工过程的NLRP3炎性小体,会引发血管壁炎症反应并导致动脉粥样硬化进展。NLRP3炎性小体被各种危险信号激活,如巨噬细胞中的胆固醇晶体、磷酸钙晶体和氧化型低密度脂蛋白,从而在动脉粥样硬化病变中引发炎症反应。最近的研究进一步阐明了针对NLRP3炎性小体的调控机制和潜在治疗药物。在本研究中,我们综述了关于NLRP3炎性小体在动脉粥样硬化发病机制中作用的现有知识,并讨论了针对NLRP3炎性小体的治疗方法。